Cajal Neuroscience Funding: $96M Raised, Series A (2022)
Cajal Neuroscience is a Biotech company based in Seattle. It has raised $96M in total funding. Latest round: Series A.
Cajal Neuroscience funding overview
Cajal Neuroscience is a Biotech company based in Seattle. Cajal Neuroscience has raised $96M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in November 2022. The round record for Cajal Neuroscience runs through 2022; nothing later has been disclosed. Investors on record include The Column Group, Lux Capital, Two Sigma Ventures, Evotec, Bristol Myers Squibb, Dimension Capital and 3 others. 9 distinct backers are named across the disclosed rounds.
Cajal Neuroscience at a glance
Total raised
$96M
Latest round
Series A
Latest round date
November 2022
Industry
Biotech
Headquarters
Seattle
Notable investors
The Column Group, Lux Capital, Two Sigma Ventures, Evotec, Bristol Myers Squibb, Dimension Capital, LGF, Alexandria Venture Investments
Frequently asked about Cajal Neuroscience funding
How much has Cajal Neuroscience raised?
Cajal Neuroscience has raised $96M in total disclosed funding across the rounds on record.
Who has invested in Cajal Neuroscience?
The Column Group, Lux Capital, Two Sigma Ventures, Evotec, Bristol Myers Squibb, Dimension Capital are named among the investors backing Cajal Neuroscience.
What was the latest Cajal Neuroscience funding round?
The most recent disclosed round is a Series A, announced in November 2022.
Where is Cajal Neuroscience based?
Cajal Neuroscience is based in Seattle.
What sector does Cajal Neuroscience operate in?
Cajal Neuroscience is tracked under Biotech from Seattle, with $96M in disclosed funding.
When did Cajal Neuroscience last raise?
The last disclosed Cajal Neuroscience round closed in November 2022 at Series A.
Cajal Neuroscience totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in Seattle below to benchmark round size and investor mix.
